Daraxonrasib Doubles Survival in Metastatic Pancreatic Cancer Trial

A Phase 3 trial of the oral targeted drug daraxonrasib (RMC‑6236) in patients with previously treated metastatic pancreatic cancer showed a median overall survival of 13.2 months, compared with 6.7 months for standard chemotherapy, effectively nearly doubling survival and cutting the risk of death by about 60%. The study enrolled 500 patients and demonstrated that the drug, which inhibits the KRAS‑driven signaling pathway long considered “undruggable,” can substantially extend life in a disease with historically poor outcomes.

The U.S. Food and Drug Administration granted an expanded‑access program, allowing eligible patients to receive the investigational therapy before formal approval. However, high demand and administrative steps have created delays in drug availability. Common adverse events reported include rash, mouth sores, diarrhea, nausea and fatigue, though discontinuation due to toxicity was low.

Revolution Medicines, the developer of daraxonrasib, is preparing regulatory submissions in the United States and Europe, aiming for approval as a second‑line treatment for advanced pancreatic cancer. Experts view the results as a major advance for a cancer type that has seen few effective new therapies.